Physician profile
Ann Samuels
NPI 1295056729
$3,550.62
in general payments reported to CMS, 2019-2025
19 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $591 · 2023: $912 · 2024: $1,086 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $745.55 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $483.22 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $330.97 | 2022-2025 | Farxiga |
| Horizon Therapeutics Plc | $262.02 | 2021-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $203.94 | 2023-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $201.07 | 2023-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $177.31 | 2021-2023 | Lupkynis |
| Ardelyx, INC. | $171.18 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $167.13 | 2021-2025 | Krystexxa, Tavneos, Aranesp |
| Novartis Pharmaceuticals Corporation | $162.04 | 2023-2025 | |
| Glaxosmithkline, LLC. | $119.62 | 2023 | Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.90 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $105.60 | 2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $95.81 | 2023-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $82.47 | 2024-2025 | Purified Cortrophin Gel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $35.71 | 2024 | |
| Dexcom, INC. | $34.61 | 2023 | Dexcom G6 Transmitter |
| Akebia Therapeutics INC | $31.65 | 2024 | Auryxia |
| Otsuka America Pharmaceutical, INC. | $27.82 | 2024 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Samuels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.